Anti-mesothelin chimeric antigen receptor T cell therapy - Pell Bio-Med Technology
Alternative Names: Mesothelin CAR-TLatest Information Update: 21 Apr 2022
Price :
$50 *
At a glance
- Originator Pell Bio-Med Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 21 Apr 2022 Preclinical trials in Cancer in Taiwan (Parenteral), prior to April 2022 (Pell Bio-Med Technology pipeline, April 2022)